Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial.
Trials
August 2020
Distinguished Investigator at Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain.
Objectives: To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8 hourly thrice a day for 5 days), versus oseltamivir (75 mg orally twice a day for 5 days), and versus Azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alone and in combination (in all seven groups), in clearing the coronavirus (COVID-19) nucleic acid from throat and nasal swab and in bringing about clinical improvement on day 7 of follow-up (primary outcomes).
Trial Design: An adaptive design, set within a comprehensive cohort study, to permit flexibility in this fast-changing clinical and public health scenario. The randomized study will be a multicenter, multiarm, multistage, randomized controlled trial with a parallel design.
A novel approach to directly observed therapy for tuberculosis in an HIV-endemic area.
Am J Public Health
January 2001
Division of Epidemiology, School of Public Health, Department of Medicine, School of Medicine, University of Minnesota, Minneapolis, USA.
Objectives: This study evaluated a novel approach to the delivery of directly observed therapy (DOT) for tuberculosis in Haiti.
Methods: A total of 194 patients (152 HIV seropositive, 42 HIV seronegative) received daily unsupervised triple-drug therapy for 4 to 8 weeks, followed by twice-weekly 2-drug therapy for the remainder of the 6-month period. DOT was deferred until initiation of the twice-weekly phase.
Does the donor-recipient ABO blood group compatibility status predict subsequent lung transplantation outcomes?
J Heart Lung Transplant
August 1999
Daniel Boone Clinic, Harlan, Kentucky 40831, USA.
Background: The study was conducted to compare lung transplantation outcomes between ABO-identical (AI) and ABO-compatible (AC) recipients.
Methods: Charts of lung allograft recipients transplanted between February, 1990 and October, 1995 were reviewed. Standard triple-drug immunosuppression and general antimicrobial prophylaxis were provided.
In vivo immunoadsorption of antipig antibodies in baboons using a specific Gal(alpha)1-3Gal column.
Transplantation
November 1996
Oklahoma Transplantation Institute, Baptist Medical Center, Oklahoma City, USA.
The major role of anti-alphaGal antibodies in the hyperacute rejection of pig organs by humans and baboons has been clearly demonstrated. Spacered alpha-galactose disaccharide (Gal(alpha1)-3Gal) hapten was produced by chemical synthesis and covalently attached to a flexible, hydrophilic polymer (PAA), which in turn was covalently coupled to macroporous glass beads, forming an immunoadsorbent that is mechanically and chemically stable and can be sterilized. The extracorporeal immunoadsorption (EIA) of anti-alphaGal antibodies using this column has been investigated in vivo in 3 baboons.
View Article and Find Full Text PDFUse of flexible triple-drug immunosuppressive therapy in liver transplantation.
Transplant Proc
October 1987
Unité de chirurgie hépato-biliaire, hopital Paul Brousse, Villejuif, France.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!